Potrony Mateu, MíriamPuig Butillé, Joan AntonAguilera, PaulaBadenas Orquin, CeliaCarrera Álvarez, CristinaMalvehy, J. (Josep)Puig i Sardà, Susana2019-03-012019-03-012014-110190-9622https://hdl.handle.net/2445/129429BACKGROUND: Cyclin-dependent kinase inhibitor 2A (CDKN2A) is the major high-risk susceptibility gene for melanoma. OBJECTIVE: We sought to evaluate the effect of CDKN2A mutations in Spanish patients with a high risk of developing melanoma and the association with clinical and family history features. METHODS: A cross-sectional study design was used to analyze the CDKN2A impact in 702 Spanish patients with a high risk of developing melanoma. RESULTS: The CDKN2A mutation prevalence was 8.5% in patients with sporadic multiple primary melanoma and 14.1% in familial melanoma. Number of cases in the family, number of primary melanomas, and age of onset were associated with the presence of CDKN2A mutation. Having a CDKN2A mutation in the family increased the prevalence of other cancers (prevalence ratio [PR] 2.99, P=.012) and prevalence of pancreatic (PR 2.97, P=.006), lung (PR 3.04, P<.001), and breast (PR 2.19, P=.018) cancers but not nephrourologic or colon cancer. LIMITATIONS: Smoking status was not assessed in the individuals with lung cancer. CONCLUSIONS: Melanoma-prone families with mutations in CDKN2A have an increased prevalence of a broad spectrum of cancers including lung, pancreatic, and breast cancer. This information should be included in genetic counseling and cancer prevention programs for CDKN2A mutation carriers.14 p.application/pdfeng(c) Elsevier, 2014Càncer de mamaCàncer de pàncreesMelanomaCàncer de pulmóGenètica mèdicaBreast cancerPancreas cancerMelanomaLung cancerMedical geneticsinfo:eu-repo/semantics/article6473822019-03-01info:eu-repo/semantics/openAccess25064638